Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 8,750,000 shares, a decline of 13.3% from the September 30th total of 10,090,000 shares. Based on an average trading volume of 801,900 shares, the days-to-cover ratio is presently 10.9 days.

Autolus Therapeutics Stock Performance

Shares of Autolus Therapeutics stock traded down $0.21 on Tuesday, reaching $4.34. 1,143,893 shares of the stock were exchanged, compared to its average volume of 1,345,284. The business has a 50 day moving average price of $4.04 and a two-hundred day moving average price of $4.07. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -3.62 and a beta of 2.04. Autolus Therapeutics has a twelve month low of $2.56 and a twelve month high of $7.45. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Analysts anticipate that Autolus Therapeutics will post -0.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AUTL. China Universal Asset Management Co. Ltd. increased its holdings in shares of Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company's stock valued at $139,000 after purchasing an additional 14,959 shares in the last quarter. Exchange Traded Concepts LLC grew its position in Autolus Therapeutics by 9.8% during the third quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company's stock valued at $152,000 after buying an additional 3,740 shares during the period. Herbst Group LLC purchased a new position in Autolus Therapeutics in the third quarter valued at $91,000. Millennium Management LLC raised its position in shares of Autolus Therapeutics by 113.7% in the second quarter. Millennium Management LLC now owns 813,031 shares of the company's stock worth $2,829,000 after acquiring an additional 432,503 shares during the period. Finally, Armistice Capital LLC boosted its stake in shares of Autolus Therapeutics by 33.8% during the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company's stock worth $21,750,000 after acquiring an additional 1,578,000 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.